TrialCirculation2017

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.

Kristina Striepe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.